We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
- Authors
Altorki, Nasser K.; Walsh, Zachary H.; Melms, Johannes C.; Port, Jeffery L.; Lee, Benjamin E.; Nasar, Abu; Spinelli, Cathy; Caprio, Lindsay; Rogava, Meri; Ho, Patricia; Christos, Paul J.; Saxena, Ashish; Elemento, Olivier; Bhinder, Bhavneet; Ager, Casey; Amin, Amit Dipak; Sanfilippo, Nicholas J.; Mittal, Vivek; Borczuk, Alain C.; Formenti, Silvia C.
- Abstract
This correction notice is related to an article published in Nature Communications titled "Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial." The correction addresses an error in the spelling of the author's name, Silvia C. Formenti, which was incorrectly written as Sylvia C. Formenti. The correction has been made to the original article. The authors of the article are Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. Formenti, Benjamin Izar, and Timothy E. McGraw.
- Subjects
NON-small-cell lung carcinoma; SURVIVAL rate; CANCER prognosis
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Correction Notice
- DOI
10.1038/s41467-023-44575-3